CVRX CVRx, Inc.
$2.88▲ +0.70%
Healthcare
Other
After hours
$2.83▼ -1.74%
Sep 11, 7:30 PM ET
Volume 1.00M
Avg Volume (10D) 601.0K
Key Metrics & Fundamentals
Market Cap
$76.73M
P/E Ratio
–
Div Yield
–%
52W Range
2.20 - 11.30
% vs 50 MA
-29.36%
% vs 200 MA
-54.88%
RSI-14
38.8
MACD Histogram
+0.0600
Beta (1Y vs SPY)
0.86
Free Cash Flow
-$8.94M
Gross Rev
$15.71M
Gross Profit
$13.72M
EBITDA
-$12.25M
COGS
$1.98M
Operating Exp
$26.75M
Operating Income
-$13.02M
EBIT
-$13.02M
Pretax Income
-$14.04M
Net Income
-$14.04M
EPS (Diluted)
-0.53
Price & Volume History
Loading chart…
Recent News

CVRx Responds to Letter from Pointillist Family Office
GlobeNewswire · Aug 25, 2026 12:00 PM

Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
PR Newswire · Aug 24, 2026 12:30 PM

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
GlobeNewswire · Aug 24, 2026 12:30 PM

CVRx (CVRX) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 13, 2026 10:15 PM

CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
MarketBeat · Aug 13, 2026 7:02 AM
CVRx Announces Sales Leadership Transition
GlobeNewswire · Aug 11, 2026 11:00 AM
Top Midday Decliners
MT Newswires · Aug 7, 2026 5:58 PM
CVRx, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 7, 2026 12:30 PM
Piper Sandler Downgrades CVRx to Neutral From Overweight, Adjusts Price Target to $4 From $12
MT Newswires · Aug 7, 2026 11:25 AM
Top Premarket Decliners
MT Newswires · Aug 7, 2026 11:18 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See CVRX's money flow as a full page
Social Sentiment
Avg +0.80 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.